bims-raghud Biomed News
on RagGTPases in human diseases
Issue of 2026–06–21
six papers selected by
Irene Sambri, TIGEM



  1. Curr Opin Cell Biol. 2026 Jun 17. pii: S0955-0674(26)00052-9. [Epub ahead of print]101 102664
      mTORC1 is a central regulator of cell growth and metabolism, classically viewed as a binary switch that promotes anabolic programs while suppressing catabolic pathways. Recent work advances this simplified model by revealing that mTORC1 signaling is highly substrate-specific, with distinct classes of substrates differentially regulated according to their modes of recruitment and subcellular localization. In this review, we discuss emerging evidence demonstrating that mTORC1 activity and its lysosomal localization can be functionally uncoupled, enabling selective phosphorylation of lysosomal versus non-lysosomal targets. We highlight how upstream regulatory pathways and post-translational modifications shape these substrate-specific outputs, and consider the implications of downstream uncoupling for the fundamental understanding of mTORC1 biology as well as human health and disease.
    DOI:  https://doi.org/10.1016/j.ceb.2026.102664
  2. Circ Res. 2026 Jun 16.
       BACKGROUND: Pathological cardiac remodeling and afterload-induced increases in energy demand together contribute to heart failure (HF). Lysosome-assisted processes, such as autophagy, coupled with alterations in mitochondrial oxidative capacity, play important roles in cardiac remodeling and HF. Furthermore, the lysosome is a hub for multiple signaling pathways governing hypertrophic growth. The TFEB (transcription factor EB) has emerged as a key regulator of lysosomal genes and mitochondrial function in multiple tissues, especially in response to external stress.
    METHODS: Leveraging a cardiomyocyte-specific TFEB knockout mouse (CTKO), pressure overload was induced by transverse aortic constriction (TAC) to elucidate the role of TFEB under hypertrophic stress conditions. Echocardiography was employed to assess cardiac function, and hearts were subsequently harvested for transcriptomic, proteomic, and metabolomic analyses. To glean further insight into the molecular mechanisms involved, we studied neonatal rat ventricular myocytes exposed to phenylephrine, an in vitro model of cardiomyocyte hypertrophy.
    RESULTS: We report that TFEB is rapidly activated and translocates to the nucleus in cardiomyocytes exposed to hypertrophic stress conditions, triggering a lysosomal gene program independent of autophagy gene changes. At baseline, contractile function measured by echocardiography appeared normal in these mice compared with their Cre-negative littermates. However, in pressure-overload stress induced by TAC, CTKO mice manifested an amplified hypertrophic response, leading rapidly to HF. Unlike WT hearts, CTKO hearts failed to increase lysosomal capacity after TAC. They manifested an increase in the steady-state levels of autophagosome-associated proteins, such as LC3II and p62, as well as accumulation of ubiquitinated proteins, suggesting a defect in protein turnover. Interestingly, CTKO mice harbored altered mitochondrial structure, reduced oxidative capacity, and reduced abundance of peroxisome PGC-1α-b (proliferator-activated receptor-1 alpha-b). Furthermore, CTKO hearts manifested reduced expression of key enzymes within metabolic pathways essential for normal myocardial metabolism, including fatty acid metabolism, carbon metabolism, and branched-chain amino acid metabolism. Surprisingly, AMPK (AMP-activated protein kinase) signaling, while normal at baseline, was significantly decreased in CTKO hearts after TAC. This reliance on TFEB for growth trigger-induced AMPK signaling was also observed in vitro in cells exposed to phenylephrine, as were the antihypertrophic effects of TFEB activation, supporting a direct role of TFEB in this process. Finally, we report that exogenous activation of AMPK in the absence of TFEB can completely rescue the exacerbated hypertrophic response both in vitro and in vivo, independent of lysosomal function. Notably, blunting of the hypertrophic response did not impact the decreased contractile function observed in TAC-treated CTKO mice, highlighting the importance of TFEB in regulating mitochondrial function in response to stress.
    CONCLUSIONS: Our findings demonstrate that TFEB antagonizes pathological hypertrophic cardiac remodeling through upregulation of lysosomal capacity, maintaining mitochondrial energetic function, and promoting AMPK signaling.
    Keywords:  autophagy; heart failure; hypertrophy; lysosomes; proteomics
    DOI:  https://doi.org/10.1161/CIRCRESAHA.125.328083
  3. Clin Kidney J. 2026 Jun;19(6): sfag143
       Background: Up to 8% of renal tumors have a monogenic cause, yet hereditary renal cell carcinoma (hRCC) syndromes such as von Hippel-Lindau (VHL), Tuberous Sclerosis Complex (TSC), Birt-Hogg-Dubé (BHD), and Hereditary Leiomyomatosis and Renal Cell Cancer remain underdiagnosed. Early diagnosis is critical for patient management, genetic counseling, and family screening. We developed and prospectively validated a structured risk assessment tool (hRCC score) for identifying patients at risk of hereditary renal tumors.
    Methods: A prospective single-center study was conducted at the University Hospital Cologne (2020-2022) including 200 patients with histologically confirmed renal tumors. The hRCC score incorporated age at diagnosis, multifocal/bilateral disease, histology, extrarenal manifestations, and family history. Patients with a score ≥1.5 were referred for genetic testing using a multiplex MLPA (Multiplex Ligand-dependent Probe Amplification)-based panel including TSC, MET, VHL, FH, SDH-A-D, and FLCN.
    Results: Of 195 eligible patients, 34.4% (n = 67) had a high-risk hRCC score (≥1.5). Overall, 71 (36.4%) underwent genetic testing; a pathogenic or likely pathogenic variant was detected in 50.7% of tested patients, corresponding to 18.5% of the total cohort. The most common diagnoses were TSC (58.3%), VHL (16.7%), and BHD (11.1%). Confirmed hereditary cases had significantly higher mean hRCC scores (4.67 vs 0.48, P < .0001). Extrarenal manifestations and bilateral or multifocal disease were the strongest predictors. The cutoff of 1.5 yielded 97.2% sensitivity and 79.8% specificity.
    Conclusions: The hRCC score is an effective clinical screening tool for detecting patients at risk for hereditary renal tumors, demonstrating high diagnostic yield and supporting targeted referral for genetic evaluation.
    Keywords:  familial renal cancer; genetic risk assessment; genetic screening; hereditary renal cell carcinoma; tumor predisposition syndrome
    DOI:  https://doi.org/10.1093/ckj/sfag143
  4. Int Rev Cell Mol Biol. 2026 ;pii: S1937-6448(25)00155-8. [Epub ahead of print]404 233-258
      Autophagy is a fundamental cell biological process that controls the quality and quantity of the eukaryotic cytoplasm. Dysfunctional autophagy, when defective or excessive, has been linked to human pathologies. Autophagy can randomly degrade cytoplasmic components in a non-selective manner commonly referred to as bulk autophagy. In contrast, selective forms of autophagy specifically target cytoplasmic structures such as organelles thereby being important for cellular quality control and organelle homeostasis. Recent studies demonstrate the role of bulk and selective autophagy in the integration of physical constraints. Mechanical forces, combine with biochemical signals control the development and the physiological functions of different organs and can also contribute to the progression of various diseases. The aim of this Review is to summarize and discuss our current knowledge on the role of autophagy in regulating a broad range of cellular responses, from morphology, metabolism, to inflammation and senescence, in the context of mechanical forces. Additionally, where relevant, we will also discuss the potential implications of mechanical stress-induced autophagy in pathologies.
    Keywords:  Bulk autophagy; Compression; ECM stiffness; Selective autophagy; Shear Stress; Stretching; Tension
    DOI:  https://doi.org/10.1016/bs.ircmb.2025.10.007
  5. Nat Commun. 2026 Jun 17.
      Heart failure (HF) is a growing global health burden characterized by impaired cardiac contractility and progressive remodeling, driven in part by disrupted Ca2+ handling and mitochondrial dysfunction. However, the molecular mechanisms coordinating these processes remain incompletely understood. Here we showed that OPA3 was decreased in both human and murine HF. Cardiomyocyte-specific deletion of Opa3 in male mice led to the progressive dilated cardiomyopathy (DCM), accompanied by impaired myocardial function, calcium cycling and mitochondria function. Mechanistically, OPA3 forms multimers that are required for its interaction with phospholamban (PLN), thereby maintaining sarcoplasmic reticulum (SR) Ca2+-ATPase (SERCA2a) activity and Ca2+ handling. OPA3 is localized to the mitochondrial outer membrane, and its absence impaired mitochondrial function. Cardiomyocyte-specific overexpression of Opa3 improved cardiac dysfunction in both pressure overload- and doxorubicin-induced HF models. Our data define a critical role of OPA3-PLN-SERCA2a axis that regulates both mitochondria and SR function, representing a potential therapeutic target for HF.
    DOI:  https://doi.org/10.1038/s41467-026-73991-4
  6. Cell Commun Signal. 2026 Jun 13.
      Cardiovascular disease remains the leading cause of global mortality, with mitochondrial dysfunction playing a central pathogenic role. Post-translational modifications act as fundamental regulators of mitochondrial quality control. Yet, how mitochondrial post-translational modifications integrate stress signals to direct cell fate among diverse regulated cell death pathways in cardiovascular disease remains incompletely understood. This review proposes a conceptual framework in which mitochondrial post-translational modifications act as the master conductors of an integrated network linking mitochondrial homeostasis to cellular demise. We first outline the pivotal roles of mitochondrial quality control in cardiovascular disease and detail their precise mechanisms governed by mitochondrial post-translational modifications over each process. We then delineate how mitochondrial post-translational modifications critically regulate the initiation and execution of apoptosis, necroptosis, pyroptosis, ferroptosis, and cuproptosis, evaluating their distinct contributions to cardiovascular pathophysiology. Furthermore, we highlight the extensive crosstalk and convergence among these death modalities at the mitochondrial level, emphasizing the role of mitochondrial post-translational modification signatures in amplifying death signals or triggering modality switching. By synthesizing recent discoveries, this work connects dynamic protein-level modifications to cell fate outcomes, offering a theoretical basis for future therapeutic strategies aimed at rebalancing the network of mitochondrial post-translational modifications to combat heart failure and other cardiovascular diseases.
    Keywords:  Cardiovascular disease; Cell death; Dynamic equilibrium.; Mmitochondrial quality control; Post-translational modifications
    DOI:  https://doi.org/10.1186/s12964-026-03002-y